Trial Profile
Phase ll trial of Amrubicin in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Jan 2022 Status changed from recruiting to completed.
- 17 Jan 2011 New trial record